Lyell Immunopharma, Inc.

NasdaqGS:LYEL Stock Report

Market Cap: US$171.1m

Lyell Immunopharma Future Growth

Future criteria checks 0/6

Lyell Immunopharma's revenue and earnings are forecast to decline at 128.2% and 14.9% per annum respectively. EPS is expected to grow by 0.6% per annum. Return on equity is forecast to be -45.7% in 3 years.

Key information

-14.9%

Earnings growth rate

0.6%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth rate-128.2%
Future return on equity-45.7%
Analyst coverage

Low

Last updated23 Dec 2024

Recent future growth updates

Recent updates

Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth

Oct 25

Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts

Apr 16

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Feb 23
Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Nov 09
Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Analysts' Revenue Estimates For Lyell Immunopharma, Inc. (NASDAQ:LYEL) Are Surging Higher

Aug 29
Analysts' Revenue Estimates For Lyell Immunopharma, Inc. (NASDAQ:LYEL) Are Surging Higher

We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth

Aug 11
We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth

Lyell Immunopharma (NASDAQ:LYEL) Is In A Good Position To Deliver On Growth Plans

Dec 15
Lyell Immunopharma (NASDAQ:LYEL) Is In A Good Position To Deliver On Growth Plans

Lyell Immunopharma gets FDA nod to start phase 1 trial of its cancer therapy LYL845

Oct 06

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Sep 12
Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

News Flash: Analysts Just Made A Huge Upgrade To Their Lyell Immunopharma, Inc. (NASDAQ:LYEL) Forecasts

Aug 08
News Flash: Analysts Just Made A Huge Upgrade To Their Lyell Immunopharma, Inc. (NASDAQ:LYEL) Forecasts

Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

Apr 29
Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth

We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth

Dec 31
We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Lyell Immunopharma's (NASDAQ:LYEL) Cash Burn Situation

Sep 17
Here's Why We're Not Too Worried About Lyell Immunopharma's (NASDAQ:LYEL) Cash Burn Situation

Earnings and Revenue Growth Forecasts

NasdaqGS:LYEL - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026N/A-283-201-1981
12/31/2025N/A-238-171-1682
12/31/20240-205-155-1523
9/30/20240-204-156-156N/A
6/30/20240-210-159-158N/A
3/31/20240-228-161-159N/A
12/31/20230-235-166-164N/A
9/30/202349-190-171-163N/A
6/30/202348-209-173-163N/A
3/31/202384-182-184-168N/A
12/31/202285-183-194-170N/A
9/30/202239-258-192-163N/A
6/30/202242-237-190-151N/A
3/31/20229-263-197-141N/A
12/31/202111-250-192-126N/A
9/30/202110-205-200-120N/A
6/30/20218-192-197-116N/A
3/31/20219-230-235-171N/A
12/31/20208-208-212-161N/A
12/31/20191-1312339N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: LYEL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: LYEL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: LYEL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: LYEL's revenue is expected to decline over the next 3 years (-128.2% per year).

High Growth Revenue: LYEL's revenue is forecast to decline over the next 3 years (-128.2% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: LYEL is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 16:46
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lyell Immunopharma, Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Geoffrey MeachamBofA Global Research
Jason ZemanskyBofA Global Research
Salveen RichterGoldman Sachs